B3 · BRL
DASA3
Diagnosticos da America S.A.
- Day's range
- R$3.88 – R$4.11
- Day's volume
- R$7.6m
- 52-week range
- R$1.28 – R$4.77
Follow DASA3 on Fuolio
See how DASA3 weighs in your net worth, what it has paid you and how far it is from your target allocation.
Create a free accountDASA3 in numbers
- Market cap
- R$5bn
- P/E
- -5.64
- P/B
- 0.74
- Dividend yield (12m)
- 0.00%
- Net debt/EBITDA
- 6.94
DASA3 price history
DASA3 risk and return
Monthly closes adjusted for splits and distributions.
| Metric | 12 months | 36 months | 60 months |
|---|---|---|---|
| Return | +193.02% | -69.44% | -91.24% |
| Volatility (annualised) | 109.31% | 76.94% | 67.97% |
| Largest drawdown | -42.51% | -89.98% | -97.12% |
| Positive months | 5/12 | 9/36 | 17/60 |
How much did investing in DASA3 return?
R$1,000.00 invested on 01/09/2021 would be worth R$87.65 today.
- Value today in DASA3
- R$87.65
- Return over the period
- -91.24%
- Return per year
- -38.55%
- In the Ibovespa
- R$1,657.66
With dividends reinvested, before taxes and costs, at month-end closes. Past returns do not guarantee future ones.
DASA3 fundamentals
Valuation
- P/E-5.64
- P/B0.74
- EV/EBITDA10.09
- EV/EBIT25.36
- EV/Revenue1.73
- P/EBIT7.93
- P/S0.54
- P/OCF11.58
- P/FCF2.65
- Earnings yield3.94%
- PEG ratio-0.21
- Earnings per share-R$0.71
- Book value per shareR$5.45
Debt
- Net debtR$11.1bn
- Net debt/EBITDA6.94
- Net debt/Equity1.62
- Debt/Equity1.76
- Current ratio1.27
- Quick ratio1.22
- Cash ratio0.28
Efficiency
- Gross margin31.02%
- EBITDA margin17.15%
- Operating margin6.83%
- Net margin-9.42%
- Asset turnover0.54
Profitability
- ROE-13.09%
- ROA-5.13%
- ROIC3.54%
- Payout—
Growth
- Revenue CAGR (5 years)0.10%
- Earnings CAGR (5 years)—
- Revenue growth (year)-27.10%
- Earnings growth (year)4.08%
- Revenue growth (quarter)-33.06%
- Earnings growth (quarter)26.22%
What is DASA3's fair price?
Two classic value formulas, with today's numbers. The current price is R$4.02.
- Graham's fair price
- —
- Does not apply to DASA3: the formula needs positive earnings and book value.
Benjamin Graham paid no more than a P/E of 15 and a P/B of 1.5. Their product, 22.5, times earnings (EPS) and book value per share gives the fair price.
- Bazin's ceiling price
- R$1.96
- 51.36% below the price
R$0.12 (5-year average) ÷ 6%
Décio Bazin only bought shares yielding at least 6% a year in distributions. The ceiling price is the average dividend per share of recent years divided by 6%.
Graham ignores growth and debt; Bazin assumes past distributions will repeat. They are reference points for comparison, not a buy recommendation.
DASA3 indicators by year
Multiples at each year's closing price; margins and returns from that year's accounts.
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| P/E | -4.95 | -1.99 | -6.36 | -19.89 | -83.48 | -231.16 | 222.38 | 46.14 |
| P/B | 0.83 | 0.30 | 0.99 | 1.09 | 2.51 | 9.86 | 8.50 | 2.56 |
| EV/EBITDA | 8.90 | 8.64 | 12.07 | 11.74 | 28.49 | 45.94 | 37.46 | 20.05 |
| Dividend yield | 0.00% | 0.00% | 0.00% | 2.19% | 0.85% | 0.78% | 0.97% | 0.50% |
| Earnings per share | -R$0.92 | -R$0.96 | -R$1.51 | -R$0.69 | -R$0.40 | -R$0.31 | R$0.26 | R$0.59 |
| Book value per share | R$5.49 | R$6.32 | R$9.74 | R$12.65 | R$13.47 | R$7.36 | R$6.79 | R$10.54 |
| ROE | -16.71% | -15.13% | -15.51% | -5.46% | -3.00% | -4.26% | 3.82% | 5.55% |
| ROIC | 4.70% | 4.08% | 3.41% | 2.79% | 0.29% | 0.98% | 4.72% | 4.75% |
| Gross margin | 30.38% | 27.37% | 27.27% | 28.93% | 29.92% | 24.94% | 35.43% | 35.51% |
| EBITDA margin | 18.14% | 16.06% | 15.50% | 16.21% | 9.77% | 13.24% | 19.83% | 15.39% |
| Net margin | -10.31% | -7.84% | -7.98% | -2.95% | -2.17% | -2.14% | 2.86% | 4.69% |
| Net debt/EBITDA | 6.09 | 7.68 | 8.79 | 8.12 | 9.91 | 8.54 | 5.39 | 6.00 |
DASA3 financial statements
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net revenue | R$11.2bn | R$15.3bn | R$14.3bn | R$13.1bn | R$10.4bn | R$7bn |
| Cost of sales | -R$7.8bn | -R$11.1bn | -R$10.4bn | -R$9.3bn | -R$7.3bn | -R$5.3bn |
| Gross profit | R$3.4bn | R$4.2bn | R$3.9bn | R$3.8bn | R$3.1bn | R$1.8bn |
| EBITDA | R$2bn | R$2.5bn | R$2.2bn | R$2.1bn | R$1bn | R$932.1m |
| EBIT | R$902.8m | R$1.1bn | R$913.3m | R$1bn | R$88.5m | R$166.6m |
| Net finance result | -R$1.5bn | -R$2.2bn | -R$1.9bn | -R$1.6bn | -R$462.7m | -R$386m |
| Profit before tax | -R$612.8m | -R$1.1bn | -R$996m | -R$578.8m | -R$374.2m | -R$219.4m |
| Income tax | -R$522m | -R$128.6m | -R$133.8m | R$191m | R$157.3m | R$71.7m |
| Net income | -R$1.2bn | -R$1.2bn | -R$1.1bn | -R$386.9m | -R$226.6m | -R$150.8m |
Figures the company filed with the CVM. Debt excludes leases; each quarter is that quarter alone.
DASA3 against its sector
The same indicators for the company's other shares and the sector's largest stocks.
| Stock | P/E | P/B | Dividend yield (12m) | ROE | Market cap |
|---|---|---|---|---|---|
| DASA3Diagnosticos Da America | -5.64 | 0.74 | 0.00% | -13.09% | R$5bn |
| RDOR3REDE DOR SÃO LUIZ S.A. | 17.79 | 4.14 | 10.99% | 23.26% | R$85.8bn |
| SAUD3SAUD3 | 37.04 | 2.09 | 3.05% | 5.63% | R$39bn |
| FLRY3FLEURY S.A. | 17.71 | 2.30 | 5.70% | 13.00% | R$12.5bn |
| HAPV3HAPVIDA PARTICIPACOES E INVESTIMENTOS SA | -19.31 | 0.07 | 0.00% | -0.36% | R$3.4bn |
| MATD3HOSPITAL MATER DEI S/A | 11.90 | 1.13 | 2.97% | 9.50% | R$1.7bn |
Does DASA3 pay dividends?
Dividend yield per year
- 0.31%2017
- 0.50%2018
- 0.97%2019
- 0.78%2020
- 0.85%2021
- 2.19%2022
- 0.00%2023
- 0.00%2024
- 0.00%2025
- 0.00%2026
| Type | Last day to own | Payment | Per share |
|---|---|---|---|
| Interest on equity | 27/12/2021 | 22/12/2022 | R$0.30 |
| Interest on equity | 12/01/2021 | 30/04/2021 | R$0.29 |
| Interest on equity | 30/12/2019 | 20/02/2020 | R$0.56 |
| Interest on equity | 28/12/2018 | 28/02/2019 | R$0.56 |
| Interest on equity | 29/12/2017 | 31/01/2018 | R$0.14 |
| Dividend | 20/04/2017 | 12/06/2017 | R$0.00 |
| Interest on equity | 29/12/2016 | 30/01/2017 | R$0.08 |
| Dividend | 25/04/2016 | 23/06/2016 | R$0.02 |
| Dividend | 23/04/2015 | 03/06/2015 | R$0.06 |
| Dividend | 28/04/2014 | 16/06/2014 | R$0.10 |
| Dividend | 22/04/2013 | 20/06/2013 | R$0.07 |
| Interest on equity | 03/10/2011 | 26/06/2012 | R$0.10 |
See all 17 distributions
| Type | Last day to own | Payment | Per share |
|---|---|---|---|
| Interest on equity | 28/12/2010 | 28/06/2011 | R$0.13 |
| Interest on equity | 10/12/2009 | 20/05/2010 | R$0.41 |
| Dividend | 25/03/2008 | 20/05/2008 | R$0.23 |
| Dividend | 11/04/2007 | 30/04/2007 | R$0.01 |
| Dividend | 27/04/2012 | — | R$0.03 |
| Event | Last day to own | Ratio |
|---|---|---|
| Split | 01/02/2010 | 4 for 1 |
About Diagnosticos Da America
- Sector
- Saúde
- Segment
- Serv.Méd.Hospit..Análises e Diagnósticos
- Listing segment
- Novo Mercado
- Tag along
- 100.00%
- Free float
- 14.12%
- Shares issued
- 1.26bn ordinary
- Average daily trading
- R$3m
- Listed since
- 19/11/2004
- CNPJ
- 61.486.650/0001-83
A Diagnósticos da América S.A. (Dasa) opera rede integrada de medicina diagnóstica, hospitais, oncologia, laboratórios de apoio e serviços de saúde digital no Brasil. A companhia atua em exames laboratoriais, imagem, análises clínicas, gestão de hospitais e coordenação de cuidado, por meio de marcas regionais e plataformas próprias. Sua receita combina atendimentos particulares, convênios, contratos corporativos e acordos com operadoras de saúde. No setor de saúde suplementar e serviços médico-hospitalares, a Dasa está entre os maiores grupos privados em escala e abrangência geográfica. O desempenho operacional depende de ocupação hospitalar, mix de procedimentos, sinistralidade, produtividade de unidades e integração clínica entre frentes diagnósticas e hospitalares. A estratégia corporativa busca capturar sinergias de rede e ampliar eficiência em uma indústria regulada e intensiva em qualidade assistencial.
Investor website| Shareholder | Ordinary | Preferred | Total |
|---|---|---|---|
| Fundo de Investimento em Participações Genoma III - MultiestratégiaControlling | 50.58% | 0.00% | 50.58% |
| FUNDO DE INVESTIMENTO EM PARTICIPAÇÕES GENOMA II - MULTIESTRATÉGIAControlling | 14.19% | 0.00% | 14.19% |
| 1122-SF FUNDO DE INVESTIMENTO EM AÇÃOControlling | 4.97% | 0.00% | 4.97% |
| GENOMA PG FUNDO DE INVESTIMENTO EM AÇÕESControlling | 4.87% | 0.00% | 4.87% |
| BANCO BTG PACTUAL S/A | 4.77% | 0.00% | 4.77% |
| DULCE PUGLIESE DE GODOY BUENOControlling | 2.87% | 0.00% | 2.87% |
| 2019RV1 FUNDO DE INVESTIMENTO FINANCEIRO AÇÕESControlling | 2.39% | 0.00% | 2.39% |
| 3921 FUNDO DE INVESTIMENTO FINANCEIRO MULTIMERCADOControlling | 2.02% | 0.00% | 2.02% |
| PEDRO DE GODOY BUENOControlling | 1.58% | 0.00% | 1.58% |
| CAMILLA DE GODOY BUENO GROSSIControlling | 1.49% | 0.00% | 1.49% |
| Outros | 9.87% | 0.00% | 9.87% |
| Ações Tesouraria | 0.42% | 0.00% | 0.42% |
Questions about DASA3
How much is DASA3 today?
DASA3 is at R$4.02 (3.61% on the day), last traded on 30/09/2026.
How much did DASA3 pay in dividends in 2025?
DASA3 paid R$0.00 per share in 2025, a dividend yield of 0.00%.
What are the P/E and P/B of DASA3?
DASA3 trades at a P/E of -5.64 and a P/B of 0.74.
How much did DASA3 return in 12 months?
DASA3 returned 193.02% in 12 months, with annualised volatility of 109.31% and a largest drawdown of -42.51%.
What sector is DASA3 in?
Diagnosticos Da America is in the Saúde sector, Serv.Méd.Hospit..Análises e Diagnósticos segment.